Objective To assess the impact of metformin use on health‐related quality of life (HRQoL) in tuberculosis (TB) patients who are presented with type 2 diabetes mellitus (T2DM). Methodology In this community‐based prospective study, TB patients attending Hakeem Abdul Hameed Centenary Hospital, New Delhi (India) and had comorbidity of T2DM between April 2018 to July 2019 were enrolled. Patients were divided into metformin users and metformin non‐users on the basis of the presence of metformin in their routine as anti diabetic drug(s). HRQoL was determined using a validated TB specific tool (Dhingra and Rajpal‐12 scale i.e. DR‐12) consists of symptom and socio‐psychological & exercise adaptation domains. The HRQoL scores were compared at pretreatment (1stvisit), end of intensive phase (2nd visit) and end of treatment (3rd visit) between the two groups. Results A total of 120 patients were enrolled, of which 24 were excluded as they did not respond at follow up visits. Among the metformin users (n=48) the mean age of patients was 47.56 years and 62.50% were males. Among the metformin non users (n=48), the mean age of patients were 49.02 years and 54.10% were males. The baseline characteristics were similar in both groups except for the substance used history (p=0.025), literacy level (p=0.048) and BMI (p=0.028). Metformin users demonstrated significant improvement in symptom scores (2nd visit: p<0.001; 3rd visit: p=0.001) and socio‐psychological and exercise adaptation scores (2nd visit: p<0.0001; 3rd visit: p<0.0001) as compared with metformin non‐users at 2nd and 3rd visit. Overall, scores were also found to be significantly improved in metformin users (2nd visit: p<0.001; 3rd visit: p=0.001). Conclusion Metformin therapy exerted favorable effects on HRQoL in patients with TB and T2DM and can be recommended as an adjuvant antitubercular drug in TB patients with co‐morbidity of T2DM, unless contraindicated.
This paper systematically and critically reviewed all published economic evaluations of drugs for the treatment of postmenopausal osteoporosis. A systematic search was conducted using relevant databases for economic evaluations to include all relevant English articles published between January 2008 to January 2020. After extracting the key study characteristics, methods and outcomes, we evaluated each article using the Quality of Health Economic Studies (QHES) and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments. A total of 49 studies met the inclusion criteria. Majority of studies were funded by the industry and reported favorable cost-effectiveness. Based on the QHES total scores, studies (n = 35) were found to be industry-funded with higher QHES mean 82.44 ± 8.69 as compared with nonindustry funding studies (n = 11) with mean 72.22 ± 17.67. The overall mean QHES scores were found to be higher 79.06 ± 11.84, representing high quality (75–100) compared to CHEERS scores (%) 75.03 ± 11.21. The statistical pairwise comparison between CHEERS mean (75.03 ± 11.21) and QHES mean (79.06 ± 11.84) were not statistically significant (P = 0.10) whereas, QHES score showed higher means as compared to CHEERS. This study suggests the overall quality of the published literatures was relatively few high-quality health economic evaluation demonstrating the cost-effectiveness of drugs for postmenopausal osteoporosis, and the majority of the literature highlights that methodological shortcoming.
1 January 2013 in Journal of Cranio-Maxillary Diseases